
|Videos|January 7, 2014
Biosimilar Interchangeability
Interchangeability designations for biosimilars would make therapy substitutions easier for pharmacists, noted Steven Lucio of Novation, but the FDA has said they will not grant an interchangeability status to a biosimilar upon initial approval.
Advertisement
Interchangeability designations for biosimilars would make therapy substitutions easier for pharmacists, noted Steven Lucio of Novation, but the FDA has said they will not grant an interchangeability status to a biosimilar upon initial approval.
This video was shot at the 2013 Academy of Managed Care Pharmacy in San Antonio, Texas.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
CMS Announces 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program
2
Immuneering Panel & CEO Insights: Atebimetinib Raises the Bar for Survival and Quality of Life in Pancreatic Cancer
3
Pharmacists Key to Rapid Plozasiran Implementation at Stony Brook
4
New 2025 Hypertension Management Guidelines Include Key Updates
5


















